ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
April 22, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Has received “Intention to Grant” from the European Patent Office For the treatment of aggression and social withdrawal MADRID, Spain and CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Oryzon...
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
April 08, 2024 08:00 ET
|
Oryzon Genomics, S.A.
MADRID, Spain and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to...
ORYZON to Provide Corporate Progress Updates at Several Events in April
April 05, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Investing in Oncology Forum 2024Van Lanschot Kempen Life Sciences Conference Swiss Biotech Day 2024LSX World Congress MADRID, Spain and BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics,...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023
February 26, 2024 14:28 ET
|
Oryzon Genomics, S.A.
Topline data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) reported with promising results in secondary endpoints of overall severity and control of...
ORYZON to Provide Corporate Progress Updates at Several Events in February-March
February 05, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Keystone Symposia Epigenetic Mechanisms and Cancer TreatmentBio-Neuroscience17th Annual European Life Sciences CEO Forum BIO-Europe Spring 2024 MADRID, Spain and BOSTON, Feb. 05, 2024 (GLOBE...
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
January 19, 2024 08:00 ET
|
Oryzon Genomics, S.A.
MADRID, Spain and BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)
January 05, 2024 15:47 ET
|
Oryzon Genomics, S.A.
Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT. An executive summary of the data to be presented at the 7th Sachs Annual Neuroscience Innovation Forum, on...
ORYZON to Provide Corporate Progress Updates at Several Events in January
January 03, 2024 08:00 ET
|
Oryzon Genomics, S.A.
7th Sachs Annual Neuroscience Innovation Forum13rd Annual LifeSci Advisors Corporate Access EventBiotech Showcase-2024 42nd Annual J.P. Morgan Healthcare ConferenceInvest Securities Biomed Forum 2024 ...
ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.
December 04, 2023 08:00 ET
|
Oryzon Genomics, S.A.
To explore Oryzon’s clinical candidate ORY-4001 in ALS The ALS Association to provide 500,000 USD funding MADRID, Spain and BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN...
ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million
November 21, 2023 12:19 ET
|
Oryzon Genomics, S.A.
Funding provided by Nice & Green SA, a Swiss private investor This CB Program supersedes the previous oneTo extend its cash runway and continue the ongoing clinical trials in CNS and oncology...